Deutsche Bank’s BioMarin Pharmaceuticals BMRN Stock Holding History

Deutsche Bank’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-500	Closed	-$43K	–	4935
2017 Q1	$43K	Buy	500 +396	+381%	+$35.2K	﹤0.01%	4270
2016 Q4	$8K	Sell	104 -520	-83%	-$44.7K	﹤0.01%	4714
2016 Q3	$57K	Buy	+624	New	+$58.8K	﹤0.01%	4158
2015 Q1	–	Sell	-400	Closed	-$36K	–	5147
2014 Q4	$36K	Buy	+400	New	+$33.3K	﹤0.01%	5283
2014 Q1	–	Sell	-450	Closed	-$2K	–	5604
2013 Q4	$2K	Sell	450 -682	-60%	-$46.3K	﹤0.01%	5162
2013 Q3	$6K	Buy	1,132 +732	+183%	+$48.6K	﹤0.01%	5127
2013 Q2	$1K	Buy	+400	New	+$24.9K	﹤0.01%	5234

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Deutsche Bank's BMRN Position: Q2 2026 in Review

Deutsche Bank reduced its BioMarin Pharmaceuticals (BMRN) stake by 69% in Q2 2026, selling an estimated $15.6M and leaving 126,286 shares worth $7.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1183.

Deutsche Bank first reported a position in BMRN in Q2 2013 and has held it in 53 quarters since. The position peaked at $328M in Q4 2023. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Deutsche Bank held 126,286 shares of BioMarin Pharmaceuticals worth $7.23M as of Q2 2026.
Deutsche Bank sold 285,016 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $15.6M.
BioMarin Pharmaceuticals made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #1183 holding.
Deutsche Bank first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
Deutsche Bank's BioMarin Pharmaceuticals position peaked at $328M in Q4 2023.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.